Literature DB >> 15793161

Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis.

Vidmantas Petraitis1, Ruta Petraitiene, Pengxin Lin, Karim Calis, Amy M Kelaher, Heidi A Muray, Christine Mya-San, Diana Mickiene, John Bacher, Thomas J Walsh.   

Abstract

The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793161      PMCID： PMC1068600          DOI： 10.1128/AAC.49.4.1642-1645.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

2.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.

Authors:  A Wald; W Leisenring; J A van Burik; R A Bowden
Journal:  J Infect Dis       Date:  1997-06       Impact factor: 5.226

3.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

Review 4.  Vancomycin. A new old agent.

Authors:  M J Ingerman; J Santoro
Journal:  Infect Dis Clin North Am       Date:  1989-09       Impact factor: 5.982

Review 5.  Chronic forms of pulmonary aspergillosis.

Authors:  D W Denning
Journal:  Clin Microbiol Infect       Date:  2001       Impact factor: 8.067

Review 6.  Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review.

Authors:  E Anaissie
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

7.  Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

Authors:  A H Groll; P M Shah; C Mentzel; M Schneider; G Just-Nuebling; K Huebner
Journal:  J Infect       Date:  1996-07       Impact factor: 6.072

8.  Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations.

Authors:  John D Cleary; P David Rogers; Stanley W Chapman
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

9.  Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors.

Authors:  C Pannuti; R Gingrich; M A Pfaller; C Kao; R P Wenzel
Journal:  Cancer       Date:  1992-06-01       Impact factor: 6.860

10.  Effect of intravenous vancomycin on renal function.

Authors:  R H Eng; L Wynn; S M Smith; F Tecson-Tumang
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544
View more
  6 in total

1.  Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Vincent H Tam; Jingduan Chi; Randall A Prince; Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  The growing promise of Toll-deficient Drosophila melanogaster as a model for studying Aspergillus pathogenesis and treatment.

Authors:  Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

3.  Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis.

Authors:  Thomas J Walsh; Mark C Wissel; Kevin J Grantham; Ruta Petraitiene; Vidmantas Petraitis; Miki Kasai; Andrea Francesconi; Margaret P Cotton; Johanna E Hughes; Lora Greene; John D Bacher; Pradip Manna; Martin Salomoni; Steven B Kleiboeker; Sushruth K Reddy
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

4.  Drosophila melanogaster as a model organism for invasive aspergillosis.

Authors:  Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Methods Mol Biol       Date:  2012

5.  Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.

Authors:  Joanne Livermore; Susan J Howard; Andrew D Sharp; Joanne Goodwin; Lea Gregson; Timothy Felton; Julie A Schwartz; Catherine Walker; Bill Moser; Werner Müller; Thomas S Harrison; John R Perfect; William W Hope
Journal:  mBio       Date:  2014-01-28       Impact factor: 7.867

6.  Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.

Authors:  Javier M Gonzalez; Carlos A Rodriguez; Andres F Zuluaga; Maria Agudelo; Omar Vesga
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.